secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001367644-25-000121
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions Q1 net income surges 656% to $68M; revenue down 26% to $222.2M
--------------------------------------------------------------------------------

- Total revenues $222.2M, down 26% YoY; driven by 62% drop in NARCAN sales to $45.3M.
- Net income $68.0M ($1.19 diluted EPS) vs $9.0M prior year; adjusted EBITDA $77.6M, up 16%.
- MCM Products segment revenues $156.6M (+1%), driven by 112% increase in Smallpox MCM to $106.4M.
- Board authorized $50M share repurchase through March 2026; reaffirmed FY 2025 revenue guidance $750-$850M.
- Recent deals: $20M BioThrax contract option, $16.7M BARDA collaboration, exclusive U.S./Canada rights to KLOXXADO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000121/0001367644-25-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000121/ebs-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001367644-25-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer